Successful Aging and Frailty

Summary

Frailty is the term commonly utilized to describe the geriatric syndrome that exposes the elderly to increased risk of negative health-related events. The frailty phenotypes (PF: physical or CF: cognitive) have demonstrated to predict the major negative health-related outcomes in the old population and show extensive similarities with sarcopenia (for PF) or dementia (for CF). However, the role of neurophysiological and biological factors contributing to the physical and cognitive frail condition, and in particular in which way mitochondrial dysfunction, as well as the hypertrophic and atrophic pathways assessed by genes expression, metabolomics and microbiota composition are contributing to these frail conditions, are still under debate. Therefore, the aim of this trial will be to make evidence based on the behaviors and the strategies that promote healthy lifestyle and successful human aging.

Conditions

• Frailty Syndrome
• Cognitive Impairment
• Sarcopenia

Interventions

OTHER

Exercise Training

The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.

OTHER

Exercise Training + Cognitive Training

ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum. CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts.

OTHER

Control

NO changes in lifestyle

Sponsors & Collaborators

• Universita di Verona

  lead OTHER

Principal Investigators

• Massimo Venturelli, Ph.D. · Università degli studi di Verona

• Maria Romanelli, Ph.D. · Università degli studi di Verona

• Federico Schena, Ph.D. · Università degli studi di Verona

• Lidia Del Piccolo, Ph.D. · Università degli studi di Verona

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

80 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-09-01

Primary Completion

2022-12-31

Completion

2023-12-31

Countries

• Italy

Study Locations